Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (000881.SZ) expects a loss of 240 million to 340 million yuan in 2025, with a non-recurring loss projected between 320 million to 450 million yuan, indicating ongoing financial challenges as the company invests in market-oriented development and technology applications in healthcare and industrial sectors [1] Financial Performance - The company anticipates a negative net profit for the reporting period due to continued investments in incubation and early-stage business operations [1] - The healthcare segment, particularly in proton therapy equipment and isotope business, has seen an increase in losses compared to the previous year due to heightened R&D and marketing expenditures [1] Asset Management - The company is conducting a comprehensive review and impairment testing of its assets, planning to make provisions for potential asset impairments [1] Non-Recurring Gains and Losses - There has been a decline in non-recurring gains and losses compared to the previous year, primarily due to reduced government subsidies and equity disposal gains recognized in the current period [1]

Core Viewpoint - The company, China General Nuclear Power Technology Co., Ltd. (CGN Tech), is forecasting a significant net loss for the year 2025, with expected losses ranging from 240 million to 340 million yuan for net profit attributable to shareholders, and from 320 million to 450 million yuan for net profit after deducting non-recurring gains and losses [1] Group 1: Financial Performance - The company anticipates a negative net profit for 2025 due to ongoing investments in incubation and early-stage business operations [1] - The medical health business is expected to continue incurring losses, with increased investments in the research and marketing of proton therapy equipment and isotope business leading to a year-on-year expansion of losses [1] - Non-recurring gains and losses are projected to decrease compared to the previous year, primarily due to a reduction in government subsidies and equity disposal gains recognized in the current period [1] Group 2: Business Strategy - The company is focusing on building a market-oriented system centered around its products, emphasizing the application of nuclear technology in the medical and industrial sectors [1] - There is a positive development trend in the accelerator and new materials business, with year-on-year performance improvements [1] - The company is conducting comprehensive asset inspections and impairment tests in accordance with accounting standards, planning to make corresponding impairment provisions for assets that may be subject to impairment [1]

Financial Performance Forecast - The company expects a net loss of between 240 million yuan and 340 million yuan for the year 2025, compared to a net loss of 362.17 million yuan in the same period last year[2]. - The expected net loss attributable to shareholders after deducting non-recurring gains and losses is between 320 million yuan and 450 million yuan, compared to a loss of 512.78 million yuan in the previous year[2]. - Basic earnings per share are projected to be a loss of between 0.2539 yuan and 0.3596 yuan, compared to a loss of 0.3831 yuan per share in the same period last year[2]. - Non-recurring gains and losses have decreased compared to the previous year, primarily due to a reduction in government subsidies and equity disposal gains[5]. - The performance forecast has not been audited by registered accountants, and the final financial data will be disclosed in the 2025 annual report[3][6]. - Investors are advised to be cautious of investment risks as the performance forecast is based on preliminary calculations by the financial department[6]. Business Focus and Development - The company is focusing on the application of nuclear technology in the medical and industrial sectors, with ongoing investments in proton therapy equipment and isotope business, leading to an increased loss in the medical health segment[4]. - The company is accelerating the development of its accelerator and new materials business, which is showing positive growth trends[4]. - The company emphasizes the importance of market-oriented system construction centered around products[4]. Asset Management - The company is undergoing a comprehensive asset inspection and impairment testing, planning to make provisions for potential asset impairments[4].

Group 1 - The core point of the news is that China General Nuclear Power Technology Co., Ltd. (中广核技) experienced a stock price increase of 5.41%, reaching 9.16 CNY per share, with a trading volume of 194 million CNY and a turnover rate of 2.58%, resulting in a total market capitalization of 8.66 billion CNY [1] - The company, established on April 17, 1993, and listed on September 2, 1998, is located in Shenzhen, Guangdong Province, and its main business includes accelerator manufacturing, irradiation processing services, modified polymer materials, and nuclear environmental protection [1] - The revenue composition of the company is as follows: new materials account for 82.38%, other services 8.49%, electronic accelerators and irradiation processing 8.40%, and import-export trade 0.73% [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under Southern Fund ranks among the top shareholders of China General Nuclear Power Technology [2] - The Southern CSI 1000 ETF (512100) reduced its holdings by 43,600 shares in the third quarter, now holding 5.1927 million shares, which represents 0.62% of the circulating shares, with an estimated floating profit of approximately 2.4406 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion CNY, achieving a year-to-date return of 8.41% and a one-year return of 43.88% [2]

Key Points - China Metallurgical Group Corporation (China MCC) expects a decline of over 50% in net profit attributable to shareholders in 2025 due to losses in the real estate sector and increased asset impairment provisions [1] - JAC Motors anticipates a net loss of approximately 1.68 billion yuan in 2025, although this represents a reduction in losses compared to the previous year [2] - Northern Rare Earth forecasts a net profit increase of 116.67% to 134.60% in 2025, driven by improved sales and production efficiency in rare earth products [3] - Shenghong Technology projects a net profit increase of 260.35% to 295% in 2025, attributed to the growing demand for AI infrastructure and high-end products [4] - Lanke Technology expects a net profit increase of 52.29% to 66.46% in 2025, benefiting from strong demand in the AI industry [7] - Aiwai Electronics anticipates a net profit increase of 17.70% to 29.47% in 2025, focusing on high-value chip solutions [25] - Longxin General expects a net profit increase of 47.15% to 60.53% in 2025, driven by steady growth in its core motorcycle and general machinery businesses [28] - China One Heavy Industry predicts a net loss of 310 million to 460 million yuan in 2025, although this represents a significant reduction from the previous year's loss [35] - Kunda Technology expects a net loss of 1.2 billion to 1.5 billion yuan in 2025, impacted by industry supply-demand imbalances [34] - Daqing Energy anticipates a net loss of 1 billion to 1.3 billion yuan in 2025, although this reflects a narrowing of losses compared to the previous year [42]

Group 1 - The company, China General Nuclear Power Technology Co., Ltd. (中广核技), announced that it will hold its second extraordinary general meeting of shareholders on February 2, 2026 [1]

（编辑 任世碧） 证券日报网讯 1月16日，中广核技发布公告称，公司2026年第一次临时股东会审议通过《关于选举第十 一届董事会独立董事的议案》《关于审批第十一届董事会董事薪酬方案的议案》《关于审批公司与中广 核财务有限责任公司签署＜金融服务框架协议＞暨关联交易的议案》。 ...

（记者 贾运可） 每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ 每经AI快讯，中广核技1月16日晚间发布公告称，公司第十一届2026年第一次董事会会议于2026年1月 16日以视频通讯方式召开。会议审议了《关于选举第十一届董事会董事长的议案》等文件。 ...

中广核核技术发展股份有限公司 公司担保管理制度 第一章 总 则 第一条 为了规范中广核核技术发展股份有限公司（以下简称"公司"） 的担保行为，维护投资者的利益，保护公司的合法权益，控制公司资产运营风 险，促进公司健康稳定地发展，根据《中华人民共和国公司法》（以下简称《公 司法》）《深圳证券交易所股票上市规则》（以下简称《上市规则》）《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《深圳证券 交易所上市公司信息披露指引第 5 号-交易与关联交易》、中国证监会《上市公 司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》等相关法律 法规以及《公司章程》《公司授权管理规定》《公司资金管理制度》、国有资产 监督管理部门对于担保管理有关规定，制定本制度。 第二条 本制度的主要内容包括担保业务的工作职责以及在担保申请、 调查评估、担保审批、日常管理、信息披露等方面的具体规定。 第三条 本制度适用于公司及各成员公司。 第四条 本文件相关的名词解释如下： （一）公司：中广核核技术发展股份有限公司。 （二）成员公司：指公司直接、间接控股或实际管理的各级公司（含托管 公司）。 （三）各公司：公 ...

本制度的编制主要根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司章程指引》《上市公司治理准则》《深圳证券交易所股票上市规则》 （以下简称"《上市规则》"）《深圳证券交易所上市公司自律监管指引第 7 号— —交易与关联交易》等有关法律、法规、规范性文件及《中广核核技术发展股 份有限公司公司章程》（以下简称"《公司章程》"）的有关规定，并结合了公司 的实际情况。 第二条 公司与关联方之间的关联交易行为除遵守有关法律、法规、规范 性文件和《公司章程》的规定外，还需遵守本制度的相关规定。 第二章 关联方和关联关系 中广核核技术发展股份有限公司 关联交易管理制度 第一章 总 则 第一条 为保证中广核核技术发展股份有限公司（以下简称"公司"）与关 联方之间的关联交易符合公平、公正、公开的原则，确保公司的关联交易行为 不损害公司、非关联股东及其他投资者的合法权益，特制订本制度。 第三条 公司关联方包括关联法人（或者其他组织）和关联自然人。 第四条 具有以下情形之一的法人或者其他组织，为公司的关联法人（或者 其他组织）： （一）直接或间接地控制公司的法人（或者其他组织）； （二）由前项所述法人（或者其他组织） ...